 |
|
New Osteoporosis Treatment
Rebecca Voelker, JAMA contributor
JAMA. 1998;279:1058.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Researchers from Denmark and the United States have discovered an effective nonestrogen treatment for osteoporosis in postmenopausal women.
In February's Journal of Clinical Endocrinology and Metabolism, the researchers report on a study of 111 healthy, early postmenopausal women with normal bone mass who were randomized to receive risedronate bisphosphonate or a placebo for 2 years. The effect on bone mass was determined by measuring bone mineral density and levels of biochemical bone markers in the blood and urine.
A year after treatment ended, women who received 5 mg daily of risedronate had a 1.4% increase from baseline in bone mineral density of the lumbar spine. The increase in the risedronate group, which was statistically significant, was 5.7% higher than in women in the placebo group. Authors of the study said their findings show risedronate offers an effective alternative to women who experience adverse effects from . . . [Full Text of this Article]
|
